Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit

Abstract

Background

The therapeutic goal for multiple sclerosis (MS) is to achieve a better long-term outcome. However, since available data come from short-term studies, it is important to review the evidence that current therapies provide long-term benefit.

Method and results

Long-term data from both registry studies and long-term follow-up studies, and efficacy treatment data were reviewed. Registry data show that the course of MS is predictable after a certain level of disability is reached, indicating that short-term efficacy data from randomized, controlled trials provide evidence of long-term benefit. Long-term studies of patients originally enrolled in pivotal randomized, controlled trials consistently show that delayed or discontinued treatment provides less benefit than continuous therapy. The 16-Year Long-Term Follow-Up Study of interferon beta-1b (IFNβ-1b; Betaferon®/Betaseron®) therapy had the highest ascertainment of long-term follow-up efforts of the pivotal trials, which led to the currently approved therapies. Disability scores at the start of treatment were predictive of their current disability scores. In addition, this 16-year study showed an excellent safety profile with no unexpected side effects to IFNβ-1b and a lower mortality rate after 16 years compared with those receiving placebo treatment during the pivotal study (6 deaths vs 20 deaths).

Conclusion

This article reviews the key data and provides recommendations for optimizing clinical studies in MS to demonstrate long-term patient benefit.

Keywords

immunomodulatory interferon β multiple sclerosis long term

Get full access to this article

View all access options for this article.

References

1 The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–661.

2 Paty DW Li DK . the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 662–667.

3 The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45: 1277–1285.

4 Johnson KP Brooks BR Cohen JA . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45: 1268–1276.

5 The PRISMS Study Group . Randomised double-blind placebo-controlled study of interferon b-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498–1504.

6 Jacobs LD Cookfair DL Rudick RA . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285–294.

7 Ford CC Johnson KP Lisak RP . A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006; 12: 309–320.

8 Trojano M Pellegrini F Fuiani A . New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300–306.

9 Ebers G Rice G Konieczny A . The interferon beta-1b 16-year long-term follow-up study: the final results. Neurology 2006; 66(Suppl. 2): A32.

10.

10 Confavreux C Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606–616.

11.

11 Kremenchutzky M Rice GP Baskerville J Wingerchuk DM Ebers GC . The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584–594.

12.

12 Rudick RA Goodkin DE Jacobs LD . Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997; 49: 358–363.

13.

13 Jacobs LD Beck RW Simon JH . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000; 343: 898–904.

14.

15.

15 Comi G Filippi M Barkhof F . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–1582.

16.

16 Kappos L Polman CH Freedman MS . Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndrome. Neurology 2006; 67: 1242–1249.

17.

17 Kappos L Freedman MS Polman CH . Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397.

18.

18 Freedman MS Kappos L Polman CH . Impact of early interferon beta-1b treatment on disease evolution over five years in patients with a first even suggestive of multiple sclerosis. Mult Scler 2008; 14: S295–S296.

19.

19 Herndon RM Rudick RA Munschauer FE . Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409–419.

20.

20 Fisher E Rudick RA Simon JH . Eight-year follow-up of brain atrophy in patients with MS. Neurology 2002; 59: 1412–1420.

21.

21 Rudick RA Cutter GR Baier M . Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005; 11: 626–634.

22.

22 Kappos L Traboulsee A Constantinescu C . Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944–953.

23.

23 Paty DW . Long-term observational efficacy and safety follow-up of the PRISMS cohort. Mult Scler 2003; 9(Suppl. 1): S138–S139 [abstract P555].

24.

24 Goodin D Ebers G Traboulsee A Konieczny A . for the Betaseron® LTF Study Group. The interferon beta-1b 16-year long-term follow-up study: clinical outcomes. Ann Neurol 2006; 60: S1–S160 [abstract M-3].

25.

25 Ebers G Goodin D Li D . The interferon beta-1b 16-year long-term follow-up: predictive clinical and MRI markers. Neurology 2007; 68(Suppl. 1): A277–A278.

26.

26 The PRISMS Study Group, The University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-b-1a in relapsing MS. Neurology 2001; 56: 1628–1636.

27.

27 Goodin DS Frohman EM Garmany GP . Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002; 58: 169–178.